Abstract:OBJECTIVE: To review recent studies of systemic therapy for mycosis fungoides and the Sézary syndrome (cutaneous T-cell lymphomas).DATA SOURCES: English-language articles indexed in MEDLINE from 1988 through 1994.STUDY SELECTION: All therapeutic studies were selected.DATA EXTRACTION: The data were abstracted without judgments on response criteria or patient numbers. Data quality and validity were assessed by independent author reviews.DATA SYNTHESIS: No systemic therapy cures patients with cutaneous T-cell lymphomas. Single and combined chemotherapeutic agents produce high response rates. Whether any of these is preferred is not established. A randomized trial comparing combination chemotherapy plus radiation therapy with topical therapy showed no survival benefit for the combination. Several adenosine analogs and retinoids were active, but their optimal use is uncertain. Interferons are as active as chemotherapeutic agents and may be less toxic. Interferon combined with psoralen plus ultraviolet A light therapy produces high complete response rates and long-lasting remissions. Combinations with other systemic therapies do not increase response rates. Photopheresis therapy should be regarded as experimental. Promising preliminary results were seen with interleukin-2 fusion toxins and several antibody conjugates.CONCLUSIONS: Systemic therapy should be considered effective and palliative. The principles of treating all low-grade lymphomas can be applied. Randomized trials are needed to evaluate new agents (such as a comparison of psoralen plus ultraviolet light with or without interferon), and large phase II trials are needed for new agents such as photopheresis, interleukin-2 fusion toxin, temozolomide, and others.

Cutaneous T cell lymphoma: update on treatment

Novel therapeutic approaches for cutaneous T cell lymphomas

The Tumor Microenvironment as a Therapeutic Target in Cutaneous T Cell Lymphoma

Advances in the pharmacological management of cutaneous T-cell lymphoma

EMERGING NEW THERAPIES FOR CUTANEOUS T-CELL LYMPHOMA

Pathophysiology of cutaneous T-cell lymphomas: Perspective from a French referral centre

New Molecular and Biological Markers in Cutaneous T Cell Lymphoma: Therapeutic Implications

The spectrum of cutaneous T-cell lymphomas: new insights into biology and therapy

Update in Diagnosis and Management of Primary Cutaneous B-Cell Lymphomas

Systemic Therapy of Cutaneous T-Cell Lymphomas (Mycosis Fungoides and the Sezary Syndrome)

Cell signaling in cutaneous T‐cell lymphoma microenvironment: promising targets for molecular‐specific treatment

Epigenetics Of Cutaneous T-Cell Lymphoma: Biomarkers And Therapeutic Potentials

Advances in the treatment of mycoses fungoides and Sézary syndrome: a narrative update in skin-directed therapies and immune-based treatments

Immunobiology and treatment of cutaneous T-cell lymphoma

Cutaneous T-cell lymphoma: diagnosing subtypes and the challenges

Current Concepts of the Immunobiology and Immunotherapy of Cutaneous T Cell Lymphoma: Insights Gained through Cross-talk between the Clinic and the Bench

Cutaneous T Cell Lymphoma Atlas Reveals Malignant Th2 Cells Supported by a B Cell-Rich Microenvironment

Immune Check Point Inhibitors in Primary Cutaneous T-Cell Lymphomas: Biologic Rationale, Clinical Results and Future Perspectives

Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, risk‐stratification, and management

Cutaneous T cell lymphoma atlas reveals malignant T H 2 cells supported by a B cell-rich tumor microenvironment

[Translated article] Survival Analysis and Prognostic Factors in a Case Series of 148 Cutaneous T-Cell Lymphomas